{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=49&state=Massachusetts",
    "query": {
      "state": "Massachusetts",
      "city": "Boston",
      "page": 49
    },
    "page_size": 10
  },
  "pagination": {
    "page": 49,
    "page_size": 10,
    "total_count": 21531,
    "total_pages": 2154,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=50&state=Massachusetts&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Boston&page=48&state=Massachusetts&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:21:06.069Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03170518",
      "title": "A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 171,
      "start_date": "2017-07-21",
      "completion_date": "2023-09-20",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 36,
      "location_summary": "Little Rock, Arkansas • Sacramento, California • Whittier, California + 31 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170518"
    },
    {
      "nct_id": "NCT00121147",
      "title": "Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension",
        "Pseudoexfoliation Syndrome"
      ],
      "interventions": [
        {
          "name": "Travatan",
          "type": "DRUG"
        },
        {
          "name": "Azopt",
          "type": "DRUG"
        },
        {
          "name": "Alphagan P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hermann Eye Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2003-09",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2006-02-24",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121147"
    },
    {
      "nct_id": "NCT00100347",
      "title": "Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma,",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PPI-2458",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PRAECIS Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2004-12",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-07-25",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 8,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Albuquerque, New Mexico + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100347"
    },
    {
      "nct_id": "NCT01042678",
      "title": "Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "MP0112",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2010-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-05-13",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042678"
    },
    {
      "nct_id": "NCT07203885",
      "title": "AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Promyelocytic Leukemia (APL)",
        "Acute Myeloid Leukaemia (AML)"
      ],
      "interventions": [
        {
          "name": "Unaided Review First, Then AI-Assisted Review",
          "type": "BEHAVIORAL"
        },
        {
          "name": "AI-Assisted Review First, Then Unaided Review",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Harvard Medical School (HMS and HSDM)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "2025-09-09",
      "completion_date": "2025-10-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07203885"
    },
    {
      "nct_id": "NCT05514717",
      "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER2-positive Non-Small Cell Lung Cancer",
        "HER2-positive Colorectal Cancer",
        "HER2-positive Tumors",
        "HER2 Low Breast Cancer"
      ],
      "interventions": [
        {
          "name": "XMT-2056",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Day One Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2023-01-24",
      "completion_date": "2026-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Stanford, California • Celebration, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05514717"
    },
    {
      "nct_id": "NCT00004889",
      "title": "Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "1999-12",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004889"
    },
    {
      "nct_id": "NCT05209568",
      "title": "Immune Responses to Gluten",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Celiac Disease",
        "Malabsorption Syndromes",
        "Digestive System Disease",
        "Intestinal Disease",
        "Gastrointestinal Diseases",
        "Gluten Sensitivity",
        "Celiac Disease in Children"
      ],
      "interventions": [
        {
          "name": "Gluten Powder",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "2 Years to 101 Years"
      },
      "enrollment_count": 400,
      "start_date": "2023-01-15",
      "completion_date": "2029-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boston, Massachusetts",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05209568"
    },
    {
      "nct_id": "NCT06388733",
      "title": "A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma",
        "GBM",
        "Brain Neoplasms, Adult, Malignant",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ivy Brain Tumor Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2024-06-19",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06388733"
    },
    {
      "nct_id": "NCT03246958",
      "title": "Nivolumab Plus Ipilimumab in Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2017-10-03",
      "completion_date": "2021-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-06-19",
      "last_synced_at": "2026-11-19T10:21:06.069Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03246958"
    }
  ]
}